What clinical trial phases has MemoryLift completed and where were they registered?

1. Promotional material versus clinical registry: what the sources actually are

The items labeled as “Memory Lift” in the provided results are marketing or review-style PDF pages and a commercial website review that describe MemoryLift as a “clinically‑advanced” natural supplement and reference “clinical studies and user testimonials” ^{[1] [2] [5] [6]}. Those documents do not show primary clinical-trial records or list registration identifiers (for example, NCT numbers) in the excerpts available; they read as product claims rather than registry entries ^{[1] [2] [6]}.

2. Where legitimate clinical trials are normally found

Authoritative reporting and academic reviews of Alzheimer’s therapies treat ClinicalTrials.gov as the central registry for clinical trials in the U.S., and large reviews explicitly base pipeline counts on ClinicalTrials.gov listings (the 2025 Alzheimer’s pipeline review references 182 clinical trials recorded on ClinicalTrials.gov and enumerates Phase 1, 2 and 3 trials accordingly) ^{[3] [4]}. If MemoryLift had completed formal, industry‑grade clinical phases, standard practice and these sources indicate it would be registered there ^{[3] [4]}.

3. No evidence in supplied science and institutional sources

The supplied authoritative sources — the Alzheimer’s pipeline review (Wiley/PMC) and institutional clinical‑trial portals (Alzheimers.gov, NIA resources, UCSF/UCSD trial pages) — document many registered Alzheimer’s and dementia trials by phase, but none of the excerpts mention MemoryLift or show registry entries connected to that brand or formulation ^{[3] [4] [7] [8] [9] [10]}. In short, the clinical‑trial infrastructure cited in these sources exists and is the right place to look, but the provided corpus does not tie MemoryLift to it ^{[3] [4] [7]}.

4. What the marketing claims say — and what they don’t prove

Several review pages and PDFs advertising MemoryLift assert the product is “clinically‑tested” or “clinically‑advanced” and reference “clinical studies and user testimonials,” but those are marketing formulations without visible trial identifiers or links to published trial data in the supplied snippets ^{[1] [2] [5] [6]}. Marketing language can conflate ingredient‑level research (e.g., bacopa or phosphatidylserine studies) with clinical testing of a branded multi‑ingredient formulation; the promotional texts do not show that distinction clearly ^[5].

5. How to verify clinical phases and registration (actionable next steps)

To confirm which phases — if any — MemoryLift has completed and where they were registered, consult ClinicalTrials.gov and search for the product name, manufacturer, or ingredient combination; check major registries (e.g., EU Clinical Trials Register) and peer‑reviewed journals for NCT numbers or published trial results. The Alzheimer’s pipeline reviews and institutional portals cited here demonstrate that bona fide Phase 1–3 trials are publicly registered and reported; absence from those registries would mean no verifiable registered trials appear in the mainstream databases referenced by these sources ^{[3] [4] [7]}.

6. Limitations and competing viewpoints in the available reporting

Limitations: the provided search results do not include a direct query of ClinicalTrials.gov, EU registers, or peer‑reviewed trial publications for MemoryLift; therefore, this assessment cannot rule out the existence of trials beyond these documents (available sources do not mention MemoryLift trial registrations). Competing viewpoints: marketing materials claim clinical validation ^{[1] [2] [5]}, while the academic and registry‑focused sources demonstrate where credible evidence would appear and do not list MemoryLift in the excerpts provided ^{[3] [4] [7]}. That divergence suggests either a lack of registered, completed trials or that any trials were not captured in the documents supplied here.

If you want, I can search ClinicalTrials.gov and the EU Clinical Trials Register for MemoryLift or its manufacturer and report any registered trials and their phase identifiers.